Vertex Pharmaceuticals (VRTX)
Develops cystic fibrosis medicines, gene-edited cell therapy, and non-opioid pain treatment.
$510.86
vs last close−4.13 (−0.80%)
Something off on this page? Send us feedback.
Next report
Nov 2, 26
in 40 days
EPS estimate
$4.76
Revenue estimate
$3.41B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$3.98$4.06$4.52$4.80$5.03$4.47$4.73Pending
Estimate$4.02$4.25$4.29$4.57$5.11$4.24$4.74$4.76
Surprise−1.0%−4.5%+5.4%+5.0%−1.6%+5.4%−0.2%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$2.91B$2.77B$2.96B$3.08B$3.19B$2.99B$3.33BPending
Estimate$2.78B$2.86B$2.91B$3.06B$3.18B$2.99B$3.23B$3.41B
Surprise+4.6%−3.2%+2.0%+0.6%+0.2%−0.2%+3.2%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $0.00 | — | — |
| Sep 2028 | $0.00 | — | — |
| Jun 2028 | $0.00 | — | — |
| Mar 2028 | $0.00 | — | — |
| Dec 2027 | $5.67 | — | — |
| Sep 2027 | $5.30 | — | — |
| Jun 2027 | $5.02 | — | — |
| Mar 2027 | $4.69 | — | — |
| Dec 2026 | $4.75 | — | — |
| Nov 2026 | $4.76 | — | — |
| Aug 2026 | $4.74 | $4.73 | −0.2% |
| May 2026 | $4.24 | $4.47 | +5.4% |
| Feb 2026 | $5.11 | $5.03 | −1.6% |
| Nov 2025 | $4.57 | $4.80 | +5.0% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Jan 2022 | |||
| Nov 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Jan 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Feb 2019 | |||
| Oct 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Jan 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| Apr 2017 | |||
| Jan 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Jan 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $0.00 | — | — | $4.10B | — | — | — |
| Sep 2028 | $0.00 | — | — | $3.90B | — | — | — |
| Jun 2028 | $0.00 | — | — | $3.77B | — | — | — |
| Mar 2028 | $0.00 | — | — | $3.67B | — | — | — |
| Dec 2027 | $5.67 | — | — | $3.91B | — | — | — |
| Sep 2027 | $5.30 | — | — | $3.75B | — | — | — |
| Jun 2027 | $5.02 | — | — | $3.60B | — | — | — |
| Mar 2027 | $4.69 | — | — | $3.37B | — | — | — |
| Dec 2026 | $4.75 | — | — | $3.51B | — | — | — |
| Nov 2, 2026 | $4.76 | — | — | $3.41B | — | — | — |
| Aug 3, 2026 | $4.74 | $4.73 | −0.2% | $3.23B | $3.33B | +3.2% | +1.7% |
| May 4, 2026 | $4.24 | $4.47 | +5.4% | $2.99B | $2.99B | −0.2% | −1.3% |
| Feb 12, 2026 | $5.11 | $5.03 | −1.6% | $3.18B | $3.19B | +0.2% | +5.7% |
| Nov 3, 2025 | $4.57 | $4.80 | +5.0% | $3.06B | $3.08B | +0.6% | −1.0% |
| Aug 4, 2025 | |||||||
| May 5, 2025 | |||||||
| Feb 10, 2025 | |||||||
| Nov 4, 2024 | |||||||
| Aug 1, 2024 | |||||||
| May 6, 2024 | |||||||
| Feb 5, 2024 | |||||||
| Nov 6, 2023 | |||||||
| Aug 1, 2023 | |||||||
| May 1, 2023 | |||||||
| Feb 7, 2023 | |||||||
| Oct 27, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Jan 26, 2022 | |||||||
| Nov 2, 2021 | |||||||
| Jul 29, 2021 | |||||||
| Apr 29, 2021 | |||||||
| Feb 1, 2021 | |||||||
| Oct 29, 2020 | |||||||
| Jul 30, 2020 | |||||||
| Apr 29, 2020 | |||||||
| Jan 30, 2020 | |||||||
| Oct 30, 2019 | |||||||
| Jul 31, 2019 | |||||||
| Apr 30, 2019 | |||||||
| Feb 5, 2019 | |||||||
| Oct 24, 2018 | |||||||
| Jul 25, 2018 | |||||||
| Apr 26, 2018 | |||||||
| Jan 31, 2018 | |||||||
| Oct 25, 2017 | |||||||
| Jul 26, 2017 | |||||||
| Apr 27, 2017 | |||||||
| Jan 25, 2017 | |||||||
| Oct 25, 2016 | |||||||
| Jul 27, 2016 | |||||||
| Apr 27, 2016 | |||||||
| Jan 27, 2016 | |||||||
| Oct 28, 2015 | |||||||
| Jul 29, 2015 |